Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor
10.3969/j.issn.1006-0111.2017.02.020
- VernacularTitle:程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习
- Author:
Yong XIA
1
;
Xiaoxia KOU
;
Xijing YANG
;
Fuping ZHOU
;
Qian ZHANG
;
Qijun QIAN
Author Information
1. 第二军医大学附属东方肝胆外科医院生物治疗科
- Keywords:
PD-1 antibody;
advanced tumor;
tumor immunotherapy
- From:
Journal of Pharmaceutical Practice
2017;35(2):174-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer .Methods From October 2015 to March 2016 ,18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital .Clinical efficacy ,adverse reactions and progression free survival time were monitored .The quality of life were compared before and after the treatment .Results Among 18 cases , PR 5 cases ,SD 7 cases and PD 6 cases .The KPS scores for quality of life was significantly increased (P<0 .05) after treat-ment .At the end of follow-up ,5 patients died ,2 patients were lost in follow-up ,11 patients survived .The median progression free survival was 2 .6 months (95% CI:1 .8-3 .3 months) .No serious adverse reactions and abnormal laboratory results were reported .Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors .It is well tolerated and has less ad-verse reactions .The randomized control studies with larger samples are needed to further confirm our conclusions .
